myasthenia gravis association
MGA
established 1960

STRENGTH AND HOPE THROUGH CONNECTIONS

VOL. 66 ISSUE 3

MYASTHENIA GRAVIS ASSOCIATION NEWSLETTER

INSIDE THIS ISSUE

Page 01 Message from Allison: Adapting Passion
Page 03 Your Voice, Your Power: Medicare Home Infusion
Page 05 Closing the Gaps: Moving Toward Personalized Care
Page 07 Clinical Trials Updates
Page 09 What's New at the MGA?
Page 10 Where in the World is the MGA?
Page 12 Upcoming Events
Page 13 Membership Donations
Page 15 Find a Support Group

Thank You for Helping Us Raise More Than $150,000!
We're still smiling after an incredible evening of generosity and support for the Myasthenia Gravis Association! Thanks to our donors, sponsors, and supporters, we raised more than $150,000 providing resources, support groups, and educational programs for the MG community.

Thank you for believing in our mission and making this possible!

HELP US SHARE YOUR MYASTHENIA GRAVIS JOURNEY

SHARE YOUR STORY

SUBMISSIONS

Want to share your MG story or have a topic you would like to see covered? We have multiple ways for you to connect with the MG community! Email us at info@mgassociation.org.

FOLLOW US

Follow us: @themgassociation
Instagram | Facebook | YouTube

A MESSAGE FROM ALLISON

Rolling with the Punches



I think I've written something like this before but sometimes we all need a reminder that things don't always go as we expect or anticipate.

In July, my dad had open heart surgery and a valve replacement. The day of his surgery, I was riddled with anxiety and fear. The very same day my car died and added chaos to an already chaotic day. Two days later, as I did an early morning airport run to take a relative to the airport, I hit a deer with my parents' car that I was only using because mine was you know, dead. In a matter of two days, I was responsible for two cars being towed away when I was already crippled with stress. Some day this story will be funny but in the moment, it was like one more thing to have to deal with.

Because I was diagnosed with MG when I was 5, I often share that I didn't feel the brunt of receiving life altering news like others have who are in the prime of their life and receive the diagnosis. I have always considered that a blessing in my MG story.

What I do recognize is that living life with MG means you often deal with the blow of expectation and reality. You often have to alter your plans, essentially your life, to be able to accommodate life with MG. And maybe what comes with that is that those of us living with rare disease are more easily adaptable because we often deal with having to make a change in the moment.

One of the first supervisors I ever had wrote in my yearly review that I needed to work on my ability to be flexible. I often giggle about that. Living life with a rare, chronic disease requires you to be flexible and to roll with the punches. I don't think I've ever forgotten that, but perhaps some situations I handle better than others.

Last year at an Advocacy Summit I attended they talked about how you respond to things that happen to you, is in your hands. It may not always be fair, easy or even desirable, but sometimes you have to take the bull by the horn and make your way. This summer has been a good opportunity for me to take stock on how I'm responding to life's events.

The Myasthenia Gravis Association (MGA) is always here to hear your story and support your journey. We'd love to hear how you have handled bumps in the road and kept trucking forward.

With gratitude,

Allison K. Foss

Allison K. Foss | Executive Director | allisonfoss@mgassociation.org

myasthenia gravis association
MGA
established 1960

CONTACT
816-256-4100
info@mgassociation.org

Two targeted treatments for adults with **generalized myasthenia gravis (gMG)**

UCB is committed to making a difference for people living with gMG by providing two treatment options

Is it time to rethink your current gMG therapy?

For people with gMG, symptoms present themselves differently in each diagnosed individual. While most people have fluctuating muscle weakness and fatigue, these symptoms vary from person to person and can range from mild to severe.

UCB offers two treatments that target different aspects of immune function related to gMG and have different methods of administration.

Scan to explore two distinct treatments that allow you and your doctor to choose the gMG treatment that fits your needs.

UCB OFFERS TWO TREATMENTS THAT TARGET gMG DIFFERENTLY:

An FcRn blocker

Harmful antibodies that cause gMG may stay in your body longer because of FcRn (neonatal Fc receptor).

A C5 inhibitor

Harmful anti-AChR antibodies activate part of your immune system called "complement," which works to attack your muscle cells.

Targeted treatments. More options.

Ask your doctor how a targeted therapy may help you meet your gMG treatment goals.

Learn more at **UCBforGMG.com**

Inspired by **patients.**
Driven by **science.**

BE IN THE KNOW!

YOUR VOICE, YOUR POWER

MEDICARE HOME INFUSION COVERAGE: WHAT PEOPLE LIVING WITH MG NEED TO KNOW

For many people living with myasthenia gravis (MG), access to convenient and flexible treatment options can make a meaningful difference in managing daily life. A recent policy development may expand access to certain home infusion therapies for Medicare beneficiaries, creating new opportunities for eligible patients to receive treatments outside of traditional infusion settings.

Earlier this year, Congress passed the Joe Fiandra Access to Home Infusion Act as part of the Consolidated Appropriations Act of 2026. This legislation expands Medicare coverage for certain physician-administered infusion therapies provided in the home setting.

The Centers for Medicare & Medicaid Services (CMS) has now taken the next step by releasing proposed guidance to implement this legislation through the Calendar Year (CY) 2027 Home Health Prospective Payment System Proposed Rule.

What Does This Mean?

If finalized, the policy would allow eligible Medicare beneficiaries receiving qualifying infusion therapies to have the option of receiving treatment at home instead of traveling to a physician's office, hospital outpatient department, or infusion center.

Home infusion coverage under this proposal would include certain:

- Infusion drugs or biological products
- Necessary equipment and supplies
- Professional services needed to safely administer the therapy in the home

Why This Matters for the MG Community

Several MG treatments involve regular intravenous or subcutaneous administration. For individuals who require ongoing infusion therapy, traveling to treatment appointments can create additional challenges, including:

- Time away from work, school, or family responsibilities
- Transportation barriers
- Physical fatigue associated with travel and appointments
- Scheduling challenges when managing symptoms or fluctuating energy levels

Access to home-based treatment options may help reduce some of these burdens while allowing patients and their healthcare teams to determine the most appropriate care setting.

The goal of this change is to improve access, reduce barriers related to transportation and scheduling, and provide patients with more flexibility in how they receive medically necessary treatments.

Which Therapies May Qualify?

Not every infusion therapy will automatically qualify. Under the law, therapies must meet specific criteria, including:

- The medication is intended to be administered by or under the supervision of a healthcare professional.
- A qualified home infusion therapy supplier provides or supervises safe administration of the medication in the patient's home.
- The prescribing information indicates that the medication is administered intravenously or subcutaneously at least 12 times per year (approximately monthly).

CMS's proposed rule also provides additional clarification about who may provide clinical supervision, including certain qualified healthcare professionals such as registered nurses, nurse practitioners, physician assistants, clinical nurse specialists, and physicians.

YOUR VOICE, YOUR POWER

MEDICARE HOME INFUSION COVERAGE: WHAT PEOPLE LIVING WITH MG NEED TO KNOW

How You Can Get Involved

Patients, caregivers, and advocates play a vital role in improving these policies. You can:

- Share your personal experience with step therapy
- Contact your state and federal representatives
- Support advocacy organizations working on this issue
- Stay informed about legislation impacting access to care

Your voice can help drive change and improve access for others in the MG community.

What Happens Next?

CMS released the CY 2027 Home Health Proposed Rule on July 1, 2026. The public now has an opportunity to submit comments on the proposed changes before CMS issues a final rule later this year.

If finalized, the expanded Medicare home infusion benefit is expected to take effect on April 1, 2027.

The Myasthenia Gravis Association will continue monitoring this policy update and sharing information as additional details become available. We remain committed to keeping the MG community informed about changes that may impact access to care, treatment options, and quality of life.

Moving Toward Personalized CLOSING THE GAPS Care in Myasthenia Gravis

For many years, myasthenia gravis (MG) treatment followed a fairly standard approach. While many people benefited from these therapies, doctors knew that MG didn't look—or respond—the same for everyone. Today, research is helping close that gap by moving toward a more personalized approach to care.

Personalized medicine considers the unique characteristics of each person's MG rather than relying on a one-size-fits-all treatment plan. Researchers now recognize that factors such as antibody status, age at disease onset, thymoma history, symptom patterns, and overall health can all influence how MG presents and how someone responds to treatment.

One of the biggest advances has been a better understanding of the different types of MG. While acetylcholine receptor (AChR) antibodies remain the most common, testing for antibodies such as MuSK and LRP4 has expanded diagnostic options and helped clinicians better identify MG subtypes. This growing knowledge has also supported the development of targeted therapies for many people with generalized AChR-positive MG, offering new treatment options that were not available just a few years ago.

We seek the support of people living with **ocular (eye-only) myasthenia gravis** for the **MyVision study.**

We also understand that some people living with ocular myasthenia gravis (oMG) may have someone supporting them, so if you or someone you know has oMG, we would like to hear from you.

Ocular myasthenia gravis is a condition that can cause double vision, droopy eyelids, fatigue, light sensitivity, or difficulty looking in different directions. These symptoms can make everyday activities challenging like driving, reading, and watching television, even if you are already on treatment.

The MyVision study is testing a study drug to see the effects on eye-only symptoms in adults with ocular myasthenia gravis (oMG). The study is hoping to better understand oMG and its symptoms while advancing scientific research at the same time. The aim of the study is to learn how well the study drug works (efficacy) and what side effects people experience while taking it (safety).

You may be able to join the MyVision study if you:

- Are at least 18 years of age
- Have been diagnosed with oMG by a doctor
- Are **not** experiencing weakness in other muscles in your body such as your face, throat, arms, and/or legs

There are other requirements for taking part in this study, which the study team will discuss with you.

If you qualify and decide to join, you will get:

- The study drug or placebo (a placebo is similar to the study drug but contains no medicinally active ingredient)
- Close medical care and follow-up throughout the study

Reimbursement for travel and other study-related expenses may be provided.

There is an extension study called MyVisionXT that MyVision participants may have an opportunity to join. In the MyVisionXT study, all participants will receive the study drug—there is no chance of receiving placebo.

If you are interested in taking part in the MyVision study, please visit myvisionstudy.com or contact the study team to learn more:

MyVision

Inspired by patients. Driven by science.

MG0038_Flyer_v1.0_US Eng_15JAN2026



Moving Toward Personalized CLOSING THE GAPS Care in Myasthenia Gravis

Researchers are also working to identify biomarkers—measurable indicators that may help predict disease activity or treatment response. Although this field is still evolving, these discoveries may one day help healthcare providers select the most appropriate therapy earlier in a patient's treatment journey, reducing the need for trial and error.

Personalized care extends beyond laboratory testing. Your treatment plan should also reflect your daily life and individual goals. Factors such as work, family responsibilities, fatigue, other medical conditions, medication side effects, and personal preferences all play an important role in deciding which treatment options are the best fit.

While there is still much to learn, the future of MG care is becoming increasingly individualized. As research continues to advance, healthcare providers will have more tools to tailor treatment to each person's unique needs—bringing us one step closer to more effective, personalized care for everyone living with MG.

Learn More

- International Consensus Guidance for Management of Myasthenia Gravis (2020 Update)
- National Institute of Neurological Disorders and Stroke (NINDS): Myasthenia Gravis

MG CLINICAL TRIAL UPDATES

University of Kansas Medical Center

MyClad PI: Dr. Mamatha Pasnoor
ClinicalTrials.gov Identifier: NCT06463587
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

For more information contact: Samantha Colgan, scolgan@kumc.edu

RemeMG PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06456580
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

For more information: Courtney Richardson, c969r831@kumc.edu

Synergy-MG PI: Dr. Farmakidis ClinicalTrials.gov Identifier: NCT07250750
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants With Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

For more information for the KU trial location contact: Abby Davis, adavis54@kumc.edu

ARGX-113-PASS-2208 PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06298565
A non-interventional, post-authorisation safety study of patients treated with efgartigimod alfa

For more information contact: Lilli Saavedra, lsaavedra2@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06359041
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants with Generalized Myasthenia Gravis

For more information: Lillian Saavedra, lsaavedra2@kumc.edu

COUR Pharma PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06106672
A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP–106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
Experimental: ALXN1720

For more information contact: Abby Davis, adavis54@kumc.edu

MG CLINICAL TRIAL UPDATES

University of Missouri

SYNAPSE-MG PI: University of Missouri- Columbia
ClinicalTrials.gov Identifier: NCT06414954
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

For more information contact: Heather McHatton, heathermchatton@health.missouri.edu

KYSA-6 PI: University of Missouri- Columbia ClinicalTrials.gov Identifier: NCT06193889
A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis

For more information contact: Laura O'Dell, lauraodell@health.missouri.edu

UPSTREAM MG PI: University of Missouri- Columbia ClinicalTrials.gov Identifier: NCT06456580
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

For more information contact: CJ Foy, cfoy@health.missouri.edu

Are You Living With
Myasthenia Gravis (MG)?

Explore whether the UPSTREAM MG Phase 3 Clinical Study is right for you

Thefocusoftoday's MGtreatmentis shifting fromsymptom relief to targeting the immune system, where the root cause lies.

This global study is testing a drug that targets the immune system to see what effect it may have on the daily lives of those who have generalized myasthenia gravis.

Our study drug will be administered as weekly injections, some of which may be self-injected (or given by a caregiver) at home between study visits.

For information about this study, including participation requirements, **email us at study@vorbio.com**

Please discuss study participation with your treating doctor.

For more about Vor Bio, scan here.

See WHAT'S NEW At the MGA

Welcome the Manhattan, KS Support Group

We're excited to announce that the Myasthenia Gravis Association is expanding to Manhattan, Kansas! The group will meet quarterly on the second Tuesday of the scheduled month at the Manhattan Senior Center. The inaugural meeting will be held Tuesday, September 8, from 6:00 - 7:30 pm and will feature MGA Executive Director Allison Foss presenting an introduction to the MGA, including the resources, programs, and support available to the MG community.

Leading the new group is Jon Klimek, who was diagnosed with MG in February 2026. We're grateful to Jon for helping bring the MGA community to Manhattan and look forward to growing together!

2026 Meeting Dates: Please send RSVP and questions to katarinaeads@mgassocication.org

- Tuesday, September 8 | 6:00 - 7:30 pm
- Tuesday, December 8 | 6:00 - 7:30 pm

Location: Manhattan Senior Center, 301 N. 4th St., Manhattan, KS 66502

A New Look for a Growing Community

You may notice a small change to our logo and branding! As the Myasthenia Gravis Association continues to grow and serve an increasingly broader community, we've updated our logo to remove "of the Heartland."

myasthenia gravis association MGA established 1960

This change reflects the expanding reach of the MGA and our commitment to making sure everyone in the MG community feels included and represented. Just as we recently removed "KC" from our web address and can now be found at www.mgassociation.org, our updated logo better reflects who we are today—and where we're headed tomorrow.

While our name may look a little different, our mission remains the same.

WHERE IN THE WORLD IS THE MGA?

NextGen Discovery Series | Columbia, MO
In June, Kathryn Clemens, Community Program Coordinator in St. Louis, was present on the University of Missouri campus in Columbia, MO for their NextGen Discovery Series.

World Orphan Drug Congress (WODC) | Boston, MA
In June, Kathryn Clemens, Community Program Coordinator in St. Louis, joined KJT's panel at WODC. The panel titled, Decoding the Rare Disease Appointment: Insights from Real Patient-Provider Dialogue, was a great opportunity for the MGA to share our community's patient voice.

Missouri Social Care Summit 2026 | Kansas City, MO
At the end of July, Katarina Eads, our Outreach Specialist, attended Findhelp's Missouri Social Care Summit.

Uplifting Athletes/UCB Engagement | Kansas City, MO
In June, Uplifting Athletes in partnership with UCB hosted the local MG community for a Kansas City Royals game.

EXPLORE THE POSSIBILITIES

Ask your doctor about VYVGART Hytrulo (efgartigamod alfa and hyaluronidase-qvfc) and VYVGART (efgartigamod alfa-fcab)

VYVGART® Hytrulo
(efgartigimod alfa and hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

Scan the QR code or visit VYVGART.com to learn more

Questions? Call 1-833-VYVGART (1-833-898-4278)

argenx

UPCOMING EVENTS

66TH ANNUAL EDUCATIONAL CONFERENCE

myasthenia gravis association
MGA
Living Life Rare

Saturday, November 7, 2026
8:30 - 2:00 pm

Join us in person in
Kansas City or virtually!

Location: Church of the Ressurection
United Methodist Church
13720 Roe Ave.
Leawood, KS 66224

Scan to Register!

THANK YOU TO OUR AMAZING SPONSORS!

argenx · ucb Inspired by patients. Driven by science.
EMD Serono · VOR · Johnson&Johnson
Catalyst pharmaceuticals · AMGEN · REGENERON SCIENCE TO MEDICINE

Meet our Keynote Panel of Clinicians who are Living with MG:

Karl Stark, MD
living with MG

Celia Meyer, RN
living with MG

Eric May, MD
living with MG

Meet our Keynote Speaker: Mamatha Pasnoor, M.D. FAAN

Transforming MG Care: An Overview of Available and Emerging Treatments

Dr. Mamatha Pasnoor is a neurologist and professor at the University of Kansas Medical Center. As a certified member of the American Board of Psychiatry and Neurology, Dr. Pasnoor holds sub-certifications in neuromuscular medicine and neurophysiology. After completing her fellowship at the University of Kansas Medical Center, she earned her medical degree from Osmania Medical College and completed her residency there as well. Dr. Pasnoor is dedicated to providing compassionate care for neurology and neuromuscular patients, and she is proud to be associated with the Myasthenia Gravis Association, where she collaborates with other skilled professionals, including MGA Board Members, to enhance patient care and support.

UPCOMING EVENTS

THANK YOU FOR 15 YEARS OF SUPPORT!

For over 15 years, you have helped the Myasthenia Gravis Association grow, connect, and support the MG community. We are incredibly grateful to everyone who has walked alongside us—our donors, volunteers, in-person and virtual participants, sponsors, and supporters. Thank you for 15 amazing years of support!

As we celebrate this milestone, we're looking ahead to the next chapter.

SAVE THE DATE 2027!

Join us for a morning of fun, community, and support for those living with MG.

Sunday, May 23, 2026
Prairiefire | Overland Park, KS

More details coming soon.

We can't wait to celebrate 16 years with you and continue making a difference together!

Membership Donations

Cindy and John Wilkinson
Cindy Disque
Elana King
Steve and Janice Katz
April Zobel
Shannon Harris, MD
Wesley and Helen Stillian
Stephanie Hubers
Keith Asaeli
Mark and Kathy Perez
Robert and Sue Fitzthum
Stephen Nutt
William and Patricia Plummer
Rose Luedde
Danielle Kempker
Enclos Corporation
Neal Lawrence
Alan Meyer
Ashley Steele
Graham Naasz, DDS
Susan Brinskelle
Tom Anderes

In Memoriam

In memory of Barbara Koester
Mike and Amy Nervig
Kathleen Saari

SUPPORT FOR MYASTHENIA GRAVIS (MG)

Find what makes you More Than MG

Join the community of patients, caregivers, and other advocates

Whether you're looking to hear more about MG, find a friend with the same diagnosis, or receive some motivation, there's a place for you in the More Than MG community.

Visit More Than MG to explore:

- Patient stories shared through social media
- Tips for living life beyond an MG diagnosis
- Encouraging reminders and motivation
- Resources for you and your loved ones

MoreThanMG.com

Follow @MoreThanMG

Use our More Than MG Instagram filter
to help spark awareness about vision impairment.

GO TO @MoreThanMG ON INSTAGRAM TAP THE SPARKLES SEE MG ICON

SELECT THE "SEE MG" FILTER

ALEXION
AstraZeneca Rare Disease

Find A SUPPORT GROUP Near you

Arkansas

Arkansas Support Group
Quarterly Saturday | 10:00 - 11:30 am | Hybrid: Zoom or In-Person at Springdale Public Library, 405 S. Pleasant St., Springdale, AR
Open to individuals, caregivers & providers
Next Meeting – October 17, 2026
RSVP: kathrynclemens@mgassociation.org

Iowa

Iowa Support Group
Bi-Monthly on the 2nd Wednesday | 6:00 - 7:00 pm | Kirkendall Public Library, 1250 SW District Dr., Ankeny, IA
Open to individuals, caregivers & providers
Hosted by Katie Coffman, Volunteer Support Group Leader
Next Meeting – August 12, 2026
RSVP: katarinaeads@mgassociation.org

Kansas

Kansas City Coffee Club
1st Thursday of the month | 9:30 - 10:30 am | Urban Egg, 4921 W 119th St., Overland Park, KS
Coffee is Dutch treat | Open to individuals, caregivers & providers
Hosted by Janice Katz & Melissa Lathrop, Volunteer Support Group Leaders
Next Meeting – September 3, 2026
RSVP: katarinaeads@mgassociation.org

Lawrence Support Group
Quarterly on a Thursday | 5:30 -7:00 pm | Lawrence Public Library, 707 Vermont St., Lawrence, KS
Open to individuals, caregivers & providers
Next Meeting – August 27, 2026
RSVP: mckennafulton@mgassociation.org

Find A SUPPORT GROUP Near you

Kansas

Manhattan Support Group
Quarterly on the 2nd Tuesday | 6:00 - 7:30 pm| Manhattan Senior Center, 301 N 4th St., Manhattan, KS
Open to individuals, caregivers & providers
Hosted by Jon Klimek, Volunteer Support Group Leaders
Next Meeting – September 8, 2026
RSVP: katarinaeads@mgassociation.org

Wichita Support Group
Quarterly on a Saturday | 2:00 - 4:00 pm | Wichita Public Library, Alford Branch 3447 S. Meridian St., Wichita, KS
Open to individuals, caregivers & providers
Hosted by Dana Paxson, Volunteer Support Group Leaders
Next Meeting – August 22, 2026
RSVP: katarinaeads@mgassociation.org

Missouri

Eastsiders Lunch Bunch - Blue Springs
1st Wednesday of the month | 11:30 - 1:00 pm | 312 SW 19th Terrace St., Blue Springs, MO
Light lunch provided | Open to individuals, caregivers & providers
Hosted by Carol Hunt & Raymond Hankins, Volunteer Support Group Leaders
Next Meeting - September 2, 2026
RSVP to mckennafulton@mgassociation.org

Kansas City Coffee Club
1st Thursday of the month | 9:30 - 10:30 am | Urban Egg, 4921 W 119th St., Overland Park, KS
Coffee is Dutch treat | Open to individuals, caregivers & providers
Hosted by Janice Katz & Melissa Lathrop, Volunteer Support Group Leaders
Next Meeting – September 3, 2026
RSVP: katarinaeads@mgassociation.org

Greater Kansas City Support Group
Quarterly on a Saturday | 10:30 am - 12:00 pm | St. Joseph Medical Center 1000 Carondelet Dr., Kansas City, MO
Light brunch is provided | Open to individuals, caregivers & providers
Next Meeting — December 12, 2026 (Holiday BINGO)
RSVP: mckennafulton@mgassociation.org

Find A SUPPORT GROUP Near you

Missouri

Kansas City Northland Support Group
Jan-Nov, bimonthly on a Thursday | 12:00 -1:30 pm | Primrose Retirement Community, 8559 N. Line Creek Rd., Kansas City, MO
Light lunch is provided | Open to individuals, caregivers & providers
Hosted by Sandy Gardner, Volunteer Support Group Leader
Next Meeting – September 10, 2026
RSVP: mckennafulton@mgassociation.org

St. Joseph Support Group
Bimonthly | 11:00am - 1:30 pm | Cabbage Roll, 2641 Lafayette St., St Joseph, MO
Open to individuals, caregivers & providers | Lunch is Dutch treat
Hosted by Donna Whittaker, Volunteer Support Group Leader
Next Meeting - October 30, 2026
RSVP: info@mgassociation.org

Springfield Support Group
Quarterly on a Thursday | 5:30 - 7:00 pm | East Sunshine Church of Christ, 3721 E. Sunshine St., Springfield, MO
Open to individuals, caregivers & providers
Next Meeting – October 15, 2026
RSVP: kathrynclemens@mgassociation.org

Mid-Missouri Group
Quarterly on a Thursday | 5:30 - 7:00 pm | Shakespeare's Pizza South, 3911 Peachtree Dr., Columbia, MO
Open to individuals, caregivers & providers
Hosted by Jonni Sutton, Volunteer Support Group Leader
Next Meeting – November 12, 2026
RSVP: kathrynclemens@mgassociation.org

St. Louis Coffee Club
4th Thursday of the month | 10:30 - 11:30 am | St. Louis Bread Company, 10221 Manchester Rd., Kirkwood, MO
Coffee is Dutch treat | Open to individuals, caregivers & providers
Next Meeting – August 27, 2026
RSVP: kathrynclemens@mgassociation.org

St. Louis Support Group
Quarterly on a Saturday | 10:00 - 11:30 am | Glendale City Hall Auditorium, 424 N Sappington Rd., St. Louis, MO
Light brunch provided | Open to individuals, caregivers & providers
Next Meeting – August 15, 2026 | October 10, 2026
RSVP: kathrynclemens@mgassociation.org

Find A SUPPORT GROUP Near you

Nebraska

Omaha Support Group
Bimonthly | 2nd Saturday | 10:00 - 11:30 am | Immanuel Hospital (The Centennial Room) 6901 N 72nd St, Omaha, NE 68122
Open to individuals, caregivers & providers
Hosted by Dianna & Ralph McCarty, Volunteer Support Group Leaders
Next Meeting - August 8, 2026 | October 10, 2026
RSVP: katarinaeads@mgassociation.org

Virtual

Muscle Makers
3rd Wednesday of the month | 12:30 - 1:30 pm CT | Via Zoom
A virtual community for individuals with MG to bring your hobbies to life. Bring your craft and creativity to your screen while connect with others.
Hosted by Bryan Bosch, Volunteer Support Group Leader
Next Meeting – August 19, 2026 | September 16, 2026
Register at mgassociation.org or email info@mgassociation.org

MG Pride Group
Bimonthly on a Tuesday | 6:00 - 7:00 pm CT
Via Zoom | Open to individuals who identify as LGTBQ+ with MG, their allies and care partners
Hosted by Bryan Bosch, Volunteer Support Group Leader
Next Meeting – October 6, 2026
RSVP: info@mgassociation.org

Virtual Monthly Meetup
4th Monday of the month | 6:30 -7:30 pm CT via Zoom
Open to individuals, caregivers & providers
Next Meeting – April 24, 2026
Register at mgassociation.org or email info@mgassociation.org

Young Friends of the MGA– Virtual Support Group
Bimonthly via zoom| 5:30 - 6:30 pm CT | Via Zoom
Open to individuals who are generally, in their 20s, 30s and 40s
Next Meeting – August 25, 2026
RSVP: info@mgassociation.org

Become a 2026 Member of the MYASTHENIA GRAVIS ASSOCIATION

Cut and enclose in envelope. Mail to MGA address below:

I want to support the MGA by becoming a 2026

- ☐ $25.00 Basic Member
- ☐ $65.00 65th Anniversary Member
- ☐ $100.00 Sustaining Member
- ☐ $500.00 Patron Member
- ☐ $1,000.00 Lifetime Member

$_____In memory of: _____

$_____In honor of: _____

Name :_____

Address: _____

City, State, Zip:_____

Phone:_____

Email: _____

I am a: ☐ MG PATIENT ☐ RELATIVE ☐ FRIEND ☐ OTHER

MGA
2340 E. Meyer Blvd., Bld. 1, Suite 300A
Kansas City, MO, 64132

-Contributions may be tax deductible
-Make checks payable to:
Myasthenia Gravis Association

Myasthenia Gravis Association
2340 E. Meyer Blvd., Building 1, Suite 300A
Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgassociation.org
www.mgassociation.org